By 2030 COPD projected third leading cause of death worldwide – how better biomarkers could alleviate this

The World Health Organization (WHO) predicts that by 2030 Chronic obstructive pulmonary disease (COPD) will become the third leading cause of death worldwide. The disease is already the fourth leading cause of death in the US today. COPD is mainly caused by tobacco smoke and passive exposure. Epidemiological studies of nonsmokers suggest that other causes…Continue Reading…

Drug Discovery, Clues from the Clinic

Dr. John LaMattina, former R&D President at Pfizer, has declared new drug development to be “stochastic” – and for good reason. Only one drug in nine succeeds through the long, costly process of clinical trials.  For cancer, only one drug in twenty makes it to market. These numbers echo the relative success of “drug targets”…Continue Reading…

Biomarker discovery & validation: Shifting research away from silos & towards collaborative endeavours

A fundamental challenge in developing drugs for certain diseases is that there is relatively little known about the pathophysiology or the natural history of the disease. Moreover, there are only a small number of experienced clinical investigators worldwide and little scientific literature published. The consequence of this is that there is uncertainty about the disease…Continue Reading…